

Hepatitis A Outbreak Prevention and Response: Call to Action

Justin Albertson MS Zack Moore MD, MPH Gibbie Harris MSPH, BSN, RN Beth Meadows MSN, RN Susan Sullivan MS, RN-BC

August 23, 2018

Disclosures

- Justin Albertson, Zack Moore, Gibbie Harris, Beth Meadows, and Susan Sullivan have no relevant financial disclosures or conflicts of interest related to the content of this activity.
- Completion criteria: the participant must attend 100% of the 8/23/18 webinar, sign and fax back (919-733-0490) the attendance roster and complete the participant evaluation to receive 1.5 CNE contact hours.
- There is no commercial support for this activity.

Accreditation Statement

Continuing education credit will be provided through the Public Health Nursing and Professional Development (PHNPD) Unit.

Public Health Nursing and Professional Development, Department of Health and Human Services, is an approved provider of continuing nursing education by the North Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Learner Objectives

Upon completion of this presentation, you should be able to

- List the 3 high risk groups impacted by the multi-state hepatitis A outbreaks
- Outline a brief written plan to reach high risk groups in your jurisdiction
- Identify necessary vaccine storage and handling steps for your off-site vaccination outreach

Webinar Activity Purpose


 The purpose of this activity is to enable you, the learner, to assist your jurisdiction with assessment, planning, implementation and evaluation for hepatitis A outbreak prevention and response.

Hepatitis A Features

- Transmitted through ingestion of object, food, or drink contaminated with stool from an infected person
- Symptoms include: fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored stool, jaundice
- Incubation period (time between exposure and symptoms): 28 days (range 15-50 days)
- Infected persons are contagious from: 2 weeks before jaundice onset to 1 week after jaundice onset, OR from 1 week before to 2 weeks after other symptoms if no jaundice

https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepa.pdf

Hepatitis A Incidence, U.S., 2006-2016



Hepatitis A Outbreaks in the United States

- From January 2017 to July 6, 2018, over 3,700 reports of hepatitis A infections nationwide
- Outbreaks in 10 states: AR, CA, IN, KY, MI, MO, OH, TN, UT, WV
- Occurring primarily among persons experiencing homelessness, persons who use drugs, and men who have sex with men (MSM)
- High hospitalization rate among cases is common (>50%)

Hepatitis A Outbreak- Kentucky

Update for	Week 32:	Total Case Counts: 8/*									
Number of new cases (n=66):	Confirmed ^A - 0 Probable - 38 Suspected - 28	Total number of cases (n=1425):	Confirmed ^A - 477 Probable - 612 Suspected - 336								
Number of counties with new cases:	27	Total number of counties with cases:	83 (69% of KY counties)								
Number of Hospitalizations:	40	Total Number of Hospitalizations:	809 (57%)								
Number of deaths Reported [†] :	1	Total number of deaths reported [†] :	9 (<1%)								
		8 150 5 United by 150 100 100									
		50									
		0	Aug 17 Aug 17 Sep 17 Oct 17 Nov 17 Dec 17	Feb 18 Mar 18	Apr 18	May 18	Jun 18	Jul 18	Aug 18	Sep 18	Oct 18

Month of Onset

Hepatitis A Outbreak- West Virginia

West Virginia Hepatitis A Outbreak Cases* as of August 17, 2018**			Outbreak Cases of Hepatitis A by Week of Symptom Onset,																				
Number of Cases 975			West Virginia, 2018 (n=975)																				
Demographics			100						••	03		' gii	na,	20			575	,					
Age Range	12-82		120																		110		
Median Age	37]	100																	93			
Male	584 (59.9%)	Cases	80																81 8(74	4 74	,
Hospitalizations	532 (54.6%)	of Ca																64					6
Deaths	2		60														52 5	1					
Risk Factors		Number	40											33	~								
Co-infection with Hepatitis C (Information available for 843 cases)	519 (61.6%)	Ž	20	1.0				4 2		. (67	10	11 6		28 15	5 23							
Co-infection with Hepatitis B (Information available for 843 cases)	95 (11.3%)		0		018		_			<u>'</u> _				38	018 018	018	018	018	018	018	018	018	118
Reports Illicit Drug Use (Information available for 811 cases)	636 (78.4%)			1/7/2018 1/14/2018	1/21/2018	2/4/20	2/11/2018	2/18/2018	3/4/201	3/11/2018	3/25/2018	4/1/2018	4/15/201		4/29/2018 5/6/2018		5/20/2018 5/27/2018	6/3/201	6/10/2018 6/17/2018	6/24/201	7/1/2018	7/15/2018	CICCIL
Homeless	124 (12.7%)]											We	ek of	Ons	set							

63 55

7/22/2018 7/29/2018 8/5/2018

8/12/2018

Hepatitis A Outbreak in North Carolina

- 21 outbreak-associated cases statewide
 - 17 (81%) hospitalized; 0 deaths
 - 5 counties affected: Mecklenburg (17 cases), Cabarrus (1), Gaston (1), Iredell (1), Rowan (1)
- Cases occurring primarily among MSM in the Charlotte area

Case Definition

Clinical Description

An acute illness with a discrete onset of any sign or symptom consistent with acute viral hepatitis (e.g., fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain), and either a) jaundice, or b) elevated serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels.

Case Classification

Confirmed:

A case that meets the clinical criteria and is IgM anti-HAV positive*, OR

A case that has hepatitis A virus RNA detected by NAAT (such as PCR or genotyping) OR

A case that meets the clinical criteria and occurs in a person who had contact (e.g., household or sexual) with a laboratory-confirmed hepatitis a case 15-50 days prior to onset of symptoms

NC Outbreak Case Definition

Outbreak-associated case:


An acute case of hepatitis A meeting the confirmed case classification with onset on or after January 1, 2018 in a North Carolina resident who:

a) Reports at least one of the following risk factors: homelessness, drug use (injection or non-injection), or MSM status; **OR**

b) Has a hepatitis A genotype that matches a genotype predominant in a recent or current US hepatitis A outbreak; **OR**

c) Is epidemiologically linked to a person meeting one of the above criteria.

Confirmed Outbreak-associated Cases Of Hepatitis A in NC by Risk Factor, Jan. 1 2018 – August 20, 2018



Investigating Hepatitis A Cases

- 1-page supplemental questionnaire (in addition to part 2 form) captures housing status (available on CD manual)
- Please assess MSM status, use of injection or noninjection drugs, homelessness/transiency, and recent incarceration for each hepatitis A case
- Recent revisions to NC EDSS include space to enter data on all risk factors of concern

Supplemental Questionnaire

North Carolina Division of Public Health Hepatitis A Supplemental Case Report Form

Interview Date:		
Patient Information:		
Last Name:	First Name:	
Date of Birth:		
NCEDSS ID:		

Please use this form in conjunction with the Part 2 form to complete the NC EDSS hepatitis A risk history package

Has the patient ever had sexual contact with a male? (answer for male cases only) Yes
No
Unknown
Refused to answer

Risk History: From 50 days prior to onset of symptoms...

Question	Yes	No	Unk	If yes, name and location	lf yes, start date	lf yes, end date
Did the patient spend the night at a friend's or family member's home?						
Did the patient spend the night at a shelter?						
Did the patient spend the night on the street?						
Did the patient spend the night at a jail/prison/detention center?						
Did the patient spend the night at a rehab/detox/congregate living facility?						
Did the patient spend the night at another type of location?						
Did the patient work for, or volunteer at, a place that serves homeless people?						

NC EDSS Risk History Package

FROM (50 days prior to onset of symptoms):	navioral Risk and Congre			1	TO (Symptom	
ricon (so days prior to onose or opinpenno).					Onset Date):	
During the period of interest did the patient stay in any congregate living facilities or other lo primary residence? The state of the patient stay in any congregate living facilities or other lo	01. Correctional facility	•	Add New			
During the period of interest, has the patient attended any social gatherings or crowded set	ttings?	01. Correctional facility				
SUBSTANCE USE		02. Barracks				
During the timeframe specified above, has the patient used injection drugs not prescribed b	by a doctor?	03. Shelter 04. Commune				
During the timeframe specified above, has the patient used NON-injection street drugs?		05. Boarding school				
SEXUAL RISK		06. Camp				
During the timeframe displayed above, has the patient had sexual contact with a confirmed disease?	or suspected case of this	08. Rehab or detox cen	nter			
During the timeframe shown above, has the patient had sexual contact with a FEMALE?		09. Friend or family men	mber's home			
During the timeframe shown above, has the patient had sexual contact with a MALE?		10. On the street				
Specify number of male sexual partners during timeframe above		zz_No zz_Other				
Has the patient EVER had sexual contact with a MALE?		Yes V				
In what setting was the patient most likely exposed?				•		
	Other Exposure Inform	nation				
Does the patient know anyone else with similar symptoms?	•					
During the period of interest did the patient have contact with sewage or human excreta?	T					
	Food Risk and Expo	sure				
During period of interest, did the patient eat any raw or undercooked seafood or shellfish (i.	.e., raw oysters, sushi, etc	.)?	•			
Describe the source of drinking water used in the patient's home. (Check all that apply)			Bottled wa	ater supplied	by a company	
					ed from a grocery stor	е
			Municipal		water)	
			Well water	r		
Where does the patient or patient's family typically purchase groceries? Store Name:						
Did the patient eat any food items during the period of interest that came from a produce st			•			
Did the patient eat any food items during the period of interest that came from a store or ve			•			
	Occupational Expos	ure				
FROM (50 DAYS PRIOR TO SYMPTOM ONSET):				UNTIL ((SYMPTOM ONSET):	
During the period of interest did the patient do any of the following:						
Employed as food worker? (Note: Update in Risk Questions - Part 1 package)				-		
Where employed?		-				
Non-occupational food worker (e.g. potlucks, receptions) during contagious period?	No T			-		
Health Care worker or child care worker handling food or medication in the contagious	No T					
period?	NO					
Did the patient work for, or volunteer at, a place that serves homeless people?	No 🔻					
Comments						

Investigating Hepatitis A Cases (cont)

- Genotyping is generally recommended for all cases unless non-outbreak source is identified (e.g. international travel)
- Specimen should be sent to SLPH and will be forwarded to CDC for genotyping
 - Original IgM+ sample is preferred, but recollection within 30 days of onset is acceptable. At least 1 mL is required
 - Use serum separator tube or EDTA plasma labeled with patient name, date of birth. Include DHHS # 3445 form requesting hepatitis A genotyping
 - Freeze and send and dry ice

Outbreak Prevention and Response: Call to Action

Actions for Local Health Departments

- **1.** Identify partners in your communities who interact with high-risk populations
- 2. Develop a plan to increase vaccination of high-risk populations
- 3. Discuss plan with your regional immunization consultant or the state immunization office
 - Assess need for state-supplied vaccine
 - Identify and address barriers to conducting off-site vaccine clinics
- 4. Track your progress
- 5. Communicate with providers, partners, and media

Planning for Prevention

CDC Guidance for Public Health Response

 Provide hepatitis A vaccine to people who are homeless, people who use injection and non-injection drugs, MSM, and others with established risk factors who are not yet immunized

 Consider hepatitis A vaccination for anyone with ongoing, close contact with people who are homeless or people who use injection and non-injection drugs

Hepatitis A vaccination coverage, 2016-U.S.

- Coverage (≥2 doses) was
 - -9% for adults ≥19 years,
 - 13% for adults 19-49 years, and
 - 5% for adults ≥50 years
- Adults 19-49 years, coverage for blacks (10%) was lower than that for whites (14%)
- Among adults 19-49 years with chronic liver conditions, coverage was only 23%

https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2016.html#hepA

Actions for Local Health Departments

- **1.** Identify partners in your communities who interact with high-risk populations
- 2. Develop a plan to increase vaccination of high-risk populations
- 3. Discuss plan with your regional immunization consultant or the state immunization office
 - Assess need for state-supplied vaccine
 - Identify and address barriers to conducting off-site vaccine clinics
- 4. Track your progress
- 5. Communicate with providers, partners, and media

1) Identify your high-risk population

- Where are they?
- Who works with them?
- How do you successfully reach them?

1) Identify Your Partners (contd)

- LHD STD Clinics
- Indigent Care/Free Clinics
- Jails/Detention Centers
- Syringe Exchange Programs
- Methadone Clinics
- Substance Abuse Treatment Centers
- Homeless Shelters

- Behavioral Health Programs
- Hospital ED/Ambulatory Care
- FQHCs
- LGBTQ Community Orgs
- LGBTQ Pride Events
- Bars/Nightclubs

2) Develop a Plan to Increase Vaccination

- Convene your Epi Team
- Get buy-in from your local leaders
- Gather your partners
- Identify your high-risk populations
- Select your vaccination strategies

https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html

2) Develop a Plan (cont)

Follow Vaccine Storage and Handling (VSH) Principles

- a) Right equipment
- b) Right monitoring
- c) Right training
- d) Right planning
- e) Right response
- f) Right resources

https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html

3) Discuss Plan with Immunization Consultants

- Assess need for state-supplied vaccine (available for high-risk populations through Immunization Branch)
- Review your standing orders and equipment needs
- Identify and address barriers to conducting off-site vaccination clinics
- Conduct training

4) Track Your Progress

Decide how to track your metrics

- Vaccination
 - Date, venue, number of doses offered, number of doses administered
- Education
 - Date, venue, number of presentations given, number of persons reached

5) Communicate with Providers, Partners, and Media

- Use your metrics
- Give them feedback on how you are progressing
- Share your success story
- Check our website for updates

5) Educate Providers -Communication Strategy for Vaccination - example



- "I reviewed your record."
- "It's time for shots."
- "We're having a hepatitis outbreak."
- "Your situation puts you at risk."
- "I strongly recommend this vaccine."
- "Let's vaccinate today."

https://www.hpviq.org/

Action Items for NC LHD Response Phase

- Investigate hepatitis A reports upon receipt
- Plan for post exposure prophylaxis administration with CD Branch, Immunization Branch
- Discuss submission logistics of serum for CDC genotyping with CD Branch
- Identify skilled resources for enhanced interviewing
- Communicate with providers, partners and media

Hepatitis Post Exposure Prophylaxis

- Immune Globulin dosage now 0.1 ml/kg
- Give hepatitis A vaccine when IG is not available
- One dose of single-antigen HAV vaccine is 95% effective in preventing infection



Hepatitis A Vaccine Products, Reporting, Offsite Administration, etc.

Beth Meadows, RN, MSN

NC Immunization Branch

Hep A Products (Licensed in the US)

Havrix

Vaqta

Twinrix

Havrix

HAVRIX ®1

Licensed dosages and schedules for HAVRIX^{®1}

Age	Dose (ELISA units) ²	Volume (mL)	No. of doses	Schedule (mos) ³
12 mos-18 yrs	720	0.5	2	0,6-12
≥19 years	1,440	1.0	2	0,6-1 <mark>2</mark>

¹Hepatitis A vaccine, inactivated, GlaxoSmithKline.

²Enzyme-linked immunosorbent assay units.

³0 months represents timing of the initial dose; subsequent numbers represent months after the initial dose.

Adult Havrix, pre-filled syringes- currently only single antigen adult Hep A product available via the NCIP. Product availability is subject to change at any time.

Vaqta

VAQTA^{®1}

Licensed dosages and schedules for VAQTA ^{® 1}

-

Age	Dose (U.) ²	Volume (mL)	No. of doses	Schedule (mos) ³
12 mos-18 yrs	25	0.5	2	0,6-18
≥19 years	50	1.0	2	0,6-18

¹Hepatitis A vaccine, inactivated, Merck & Co., Inc.

²Units.

³0 months represents timing of the initial dose; subsequent numbers represent months after the initial dose.

Twinrix



TWINRIX^{®1} (HepAHepB) Vaccine Schedule (Not recommended for post exposure prophylaxis)

Licensed dosages and schedules for TWINRIX®1

Age	Dose (ELISA units) ²	Volume (mL)	No. of doses	Schedule
≥ 18 yrs	720	1.0	3	0, 1, 6 mos
≥ 18 yrs	720	1.0	4	0, 7, 21–30 days + 12 mos ³

¹Combined hepatitis A and hepatitis B vaccine, inactivated, GlaxoSmithKline.


²Enzyme-linked immunosorbent assay units.

³This 4-dose schedule enables patients to receive 3 doses in 21 days; this schedule is used prior to planned exposure with short notice and requires a fourth dose at 12 months.

Product Considerations


- Post-exposure vs Preexposure
- Populations Served

Post-exposure Prophylaxis



*Use IG for children aged <12 mo, immunocompromised persons, persons with chronic liver disease, and persons who are allergic to the vaccine or a vaccine component **Consider IG vs vaccine for individuals 40 and older; Vaccine can be used if IG is not available

Pre-exposure for High Risk



Administer 2 doses of Havrix or Vagta 6 months apart

Single Antigen Hep A vs. Twinrix

Known exposure to Hep A in the past two weeks? Yes- Single Antigen Documented completion of either the Hep A or Hep B series? Yes- Single Antigen Ability to complete the Twinrix series? (e.g. short term inmate vs. long term inmate)? Yes- Twinrix

Dose 2?

"While manufacturers have supply to meet current demand, CDC and vaccine manufacturers continue to monitor ongoing demand for and usage of adult Hepatitis A vaccine closely" (CDC, March 2018).

Latex Allergy?

Honotitic A	Havrix	YES – Syringe NO – Vial
Hepatitis A	Vaqta	YES – Syringe YES – Vial

Twinrix	YES – Syringe NO – Vial
---------	----------------------------



Twinrix- HepA/HepB Combination (Twinrix®)	≥ 18 years	UNINSURED ADULT USE	LHD/FQHC'RHC Only: Any uninsured adult who meets one or more of the ACIP recommended coverage groups can receive a three-dose series of the combination Hep A/Hep B vaccine at the LHD, FQHC, or RHC. State-supplied Hep A/Hep B vaccine cannot be used for the accelerated schedule, four dose series or for persons with a documented history of a completed hepatitis A or B series.
--	------------	------------------------	--

Hep A- Any high risk individual regardless of insurance status* LHDs can now order through the NCIR.

*Insurance status is still required to be assessed and documented



Community Health Assessment?

- Populations at risk
- Potential Community Partners (e.g. homeless clinics, safe syringe programs, LTGB advocacy groups)

UAT Region (T4) 10.2.0

General

system user manual Maintenance manage users manage sites manage clinicians manage physicians manage schools mass vax definition nventory

manage inventory manage orders manage transfers manage returns flumist replacement request transaction sum request vaccine usage request wasted/expired inventory report vaccine accountability inventory count

Clients manage client mass vax grid entry mmunizations

Reporting Doses- NCIR

- Enter at time of administration or by close of business day
- Can use Mass Vax Function in the NCIR





Use only for mass vaccination efforts

Can enter up to five patients at one time



Must set up a definition in order to use (use a standardized way to name your definitions (e.g. Name of Vaccine / State or Private / Lot Number)

NCIR- Mass Vax- Training Tool


https://immunize.nc.gov/providers/ncireducation.htm







<u>Reports only</u>: The reports only user is able to search for Caents and opinit cherts pecific immunization in the registry.
<u>Typical User:</u> This user may not edit or update information in the registry.
<u>Typical User:</u> This user role is the most common in the NCIR. The typical user finds, adds, and edits distance of a set of the sector of the distance of the sector.



Doses Administered Form

- Complete in addition to NCIR documentation
- Only note individuals vaccinated as part of this Hep A response (exclude routine Hep A vaccines from form)
- Submit via email or fax to the NCIP by COB each Friday

	Vaccine	patitis A Response e Reporting Form a Immunization Branch
Agency:		
Date:		
Reported by:		
Phone:		
Email:		
	ort vaccine administ	Population Vaccination tered in response to the Hepatitis A event. <u>All</u> also be documented in the NCIR.
Pro	oduct	Doses Administered
	A vaccine (ages 19 older)	
Pro	oduct	Doses Administered
Pediatric Hepati	tis A vaccine (ages	

Please submit to the Immunization Branch by close of business each Friday.

Caroline Helton- Fax: (919) 870-4824 or Email: caroline.helton@dhhs.nc.gov

Additional Screening and Documentation Forms

"Don't reinvent the wheel, just realign it" ~Anthony J. D'Angelo

North Carolina Immunization Registry

Mass Clinic Form

Chart Number:

Mass Clinic Form (NCIR homepage under "Resources on the web")

			-		
YOU MUST COMPLETE ALL FIELDS BELO	w				
Information collected on this form will be used to do		receipt of vaccine(s).			
Patient's Name (Last, First, Middle Initial)		Mother's Malden Name	Last, First, Middle Initial)	
Date of Birth (mm/dd/yyyy)	Gender	_	Ethnicity (Check One)		
	Male	Female	Hispanic	Non-Hisp	anic
Race (Check all that apply)			_	_	
	can Indian or Alaskan		White	Unknow	a
Black or African American Native	Hawaiian or Other Pa	acific Islander	Other Race		
Name of Parent or Guardian Responsible for Patient (Las	st, First, Middle Initial)		Relationship to Patien	t	
Address			P.O. Box		
City	County		State	Zip Code	
Email Address (if applicable)	Home Telephone Number		Work Telephone Num	iber Ext	ension
	()		()		
PLEASE ANSWER ALL OF THE FOL	LOWING:				
1. Is the person to be vaccinated sick to	oday?			VES	
2. Does the person to be vaccinated ha	ve an allergy to a com	ponent of the vaccin	e?	VES	
3. Has the person to be vaccinated eve	r had a serious reaction	on to influenza in the	past?	☐ YES	
4. Has the person to be vaccinated eve	r had Guillain-Barré sy	/ndrome?		TES YES	
5. Are you currently pregnant?				VES	

I am authorized by the parent, guardian, or person standing in loco parentis of the above-named child to obtain needed immunizations for the child.

I/parental designee have received the "Vaccine Information Statements" (VIS) about the disease(s) and vaccine(s). I have had a chance to review the VIS(s) and to ask questions that were answered to my satisfaction. I understand the benefits and risks of the vaccine(s) and request the vaccine(s) indicated below to be given to me or the person name davove for whom I am authorized to make this request.

SIGNATURE – Per	son to receive vaccine or pe	rson authorized to sign on	the patient's behalf	Date	Signed		
		FO	OR OFFICE USE ON	LY:			
<u>Eliaibility:</u>	American Indian/Ala	skan Native 🗌 Med	dicaid Not Insure	d Underins	ured 🔲	NC Health Choice	sured
Vaccine	Trade Name	Lot #	VIS Pub. Date	Date VIS Presented	Body Route	Body Site*	mL.
Influenza					IM	RV LV RD LD	
PPSV					IM SC	RV LV RD LD	
Other							
* RV = Right Vast	us Lateralis LV = Left Va	astus Lateralis RD = Rig	ght Deltoid LD = Left De	Itoid BN = Bilate	ral Nares R	N = Right Naris LN = Left N	aris

SIGNATURE AND TITLE - Person Administering Vaccine

Name of Organization

Date Vaccine Administered

Screening for Risk Factors and Contraindications

Identification number-

Patient name

Should You Be Vaccinated Against Hepatitis A?

A SCREENING OUESTIONNAIRE FOR ADULTS

Hepatitis A is a serious liver disease caused by the hepatitis A virus (HAV). Hepatitis A virus is found in the feces (poop) of people with hepatitis A. Hepatitis A can be spread by having close personal contact with an infected person, such as by living with or having sex with an infected person. It can also be spread by eating food or by drinking water that has been contaminated with hepatitis A virus - either when in the U.S. or when traveling in other countries. Symptoms of hepatitis A can include yellowing of the skin and eyes, nausea, fever, fatigue, belly pain, and dark urine. You can be sick for several weeks, Sometimes hepatitis A is fatal.

___ Today's date ____/___/___

The Centers for Disease Control and Prevention (CDC) recommends hepatitis A vaccination for all children in the United States when they are one year of age, certain children age 6 through 11 months who are traveling outside the U.S., all people who are in risk groups, or for people who want to avoid hepatitis A infection. Please review the list below to see if you should be vaccinated.

Some people should have their blood tested to find out if they have already been infected with hepatitis A. Talk to your healthcare provider about whether this applies to you.

You should be vaccinated if any of the following apply to you:

I want to be vaccinated against hepatitis A to avoid an infection in the future.

I travel or work in areas outside the United States where hepatitis A is common. (This includes evenwhere except Australia, New Zealand, Northern and Western Europe, Japan, and Canada.)

I have (or will have) contact with an adopted child within the first 60 days of the child's arrival from a country where hepatitis A is common. (See previous bullet for locations.)

I have chronic liver disease

I have a blood clotting-factor disorder (for example, hemophilia).

I am a man who has sex with men.

I use street drugs (injectable or noninjectable).

I might have been exposed to the hepatitis A virus in the past two weeks.



Technical instant mixed by the Center for Desertion and Desertion Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org

Screening Checklist for Contraindications to Vaccines for Adults

DATE OF BIRTH

For patients: The following questions will help us determine which vaccines you may be given today. If you answer "yes" to any question, it does not necessarily mean you should not be vaccinated. It just means additional questions must be asked. If a question is not clear, please ask your healthcare provider to explain it

	yes	no	don't know
1. Are you sick today?			
2. Do you have allergies to medications, food, a vaccine component, or latex?			
3. Have you ever had a serious reaction after receiving a vaccination?			
4. Do you have a long-term health problem with heart disease, lung disease, asthma, kidney disease, metabolic disease (e.g., diabetes), anemia, or other blood disorder?			
5. Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem?			
6. In the past 3 months, have you taken medications that affect your immune system, such as prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis, Crohn's disease, or psoriasis; or have you had radiation treatments?			
7. Have you had a seizure or a brain or other nervous system problem?			
 During the past year, have you received a transfusion of blood or blood products, or been given immune (gamma) globulin or an antiviral drug? 			
9. For women: Are you pregnant or is there a chance you could become pregnant during the next month?			
10. Have you received any vaccinations in the past 4 weeks?			
FORM COMPLETED BY	DATE		
FORM REVIEWED BY	DATE		

Did you bring your immunization record card with you? yes 🗌 no 🗌 It is important for you to have a personal record of your vaccinations. If you don't have a personal record, ask your healthcare provider to give you one. Keep this record in a safe place and bring it with you every time you seek medical care. Make sure your healthcare provider records all your vaccinations on it.



Immunization Action Coalition- www.immunize.org

Patient Record

§ 130A-154

I. Last Name		t Name			AI	N.C. D	Division of P Immunizati		
2. Patient Number				-	- н		mmunizau	on branch	
3. Date of Birth			Month	Day	Year		Adult V	accine	
4. Asia 5. Sex 🗌 1. Male	Indian/Alaska an/Pacific Islar 2. Female	k an Native nder □	Ethnicity: [5. Other:_	Hispanic O 1. Yes	rigin? 2. No	Adr	ninistrat	tion Record	
6. County of Reside									
Before administerir and benefits of the	ig any vaccines vaccine(s). Up	s, give the date the p	patient cop patient's pe	pies of all pert rsonal record	inent Vaccine Ir card or provide	nformation Sta a new one wh	tements (VISs) a nenever you admi	nd make sure he/she und inister the vaccine.	erstands the
	Date given		Site given	Va	ccine	Expiration		Consent	Signat
Vaccine	(mo/day/yr)	Route	(RA, LA)	lot #	mfr.	date	Date on VIS ¹	signature	vaccin
Tetanus and Diphtheria (e.g., Td)									
Tetanus, Diphtheria, Pertussis (Tdap)									
Hepatitis A ² (e.g., HepA, HepA-HepB)									
Hepatitis B ²									
(e.g., HepB, HepA-HepB)									
Measles, Mumps, Rubella (MMR)									
Varicella (Var)									
Pneumococcal									
Conjugate (PCV13)									
Pneumococcal Polysaccharide (PPSV23)									
Zoster (Shingles) (Zos)									
Meningococcal Conjugate (MCV4)									
Human Pappillomavirus									
(HPV)		1							
Influenza (Flu)									
		-							
		1			1	1		1	

Record the publication date of each VIB given to the patient. According to federal law, VIBs must be given to patients before administering each dose of vo "For combination vacches, fill in the row for each individual antigen composing the combination. DHHS 4057 (9/15)

Immunization (Review 9/18)



- Follow storage and handling requirements- Non-viable vaccine will not prevent disease!
- Transport and store vaccines in an approved unit (e.g. mobile vaccine unit, hard-sided cooler) using a digital data logger (Do not ship the vaccine to the site)
- Check and record vaccine temperatures hourly and at the end of the session or day
- Keep the transport unit closed as much as possible (taking out no more than one multi-dose vial or ten manufacturer pre-filled vaccine syringes at one time)
- Properly store vaccines and water bottles upon returning to facility (Do not leave vaccines in the transport unit overnight)
- Handle preventative maintenance of the cold chain equipment per manufacturer guidelines

Call the NCIP immediately for out of range temperatures-919-707-5574

Packing Vaccines for Transport during Emergencies

Be ready BEFORE the emergency

The Telescond Control of the Control of the Control of the Control of Control

1 Gather the Supplies



Hard-sided coolers or Styrofosan²⁴ vaccies shipping containers - Coolers should be large enough to: your location's typical supply of refriguenced vacciese. - Can use original shipping bases from manufacturers if available. - Do NOT use acfricted collogable: coolers.



Conditioned frozen water bottles

Use at its one hosting for machines (Magin conclusion of each better for each conclusion (except) of a layers main development and the program of the program of the second second second second second second second transformer and the second second second second second second research sector better and the second second second second layer of second second second second second second second layer of second second second second second second second layer of second seco



nsulating material — You will need two of each layer

making material — 1 do win more tools of which a single packing frame, or 3 Styroloum²⁶ for a layer above and believe the vaccines, at least in thick. Makie an ent covers the caldboard completely. Do NOT use packing persons or other loose material that might shift during transport. • Corrugated cardboard – You pieces cut to fit intradic dimensions of cooler(a) to be placed between insulating cubicoting material and conductions dimensions.




 $\begin{array}{l} \textbf{mperature monitoring deriver - Digital data logger (DEL) with buffered probe. Accuracy of <math display="inline">1/27^{-1}(1+\alpha)^{-1}$ with a current and valid certificate of adherican testing. Pre-shill balance probe that the start β hours in self-generator. Temperature monitoring device extremly stored in refrigerator can be used, as long a those is device in remember temperatures the ange remaining various energies. The start end of the start of the st

Why do you need cardboard, bubble vrzap, and conditioned frozen water bottles? Conditioned frozen write loatine and concared cardboard used alone with one into if installing material such as bubble wrap keeps religiented vectores at the right termenature and prevents them from frequent, Resulting vectore coolant pack from original vectore shipping containers can freez and damage religiented use.

U.S. Department of Health and Namas Services Centrol and Prevention Visit www.cdc.gov/vaccines/SandH for more information, or your state health department.

Updated 02/02/2018



COOLER ID		CLINIC LOCATION DATE			refrigerated and frozen vaco transporting vaccines.	
TIME	INITIALS ALARS	CURRENT		MAX	Other	Keep cooler in OK range
						2.0°C 8.0 Check temperatures ho 1. Fill out clinic details in he 2. Record the time and you
						 Record a check if an alar Record Current, MIN, an
						If no alarm:
						 Clear MIN/MAX. Ensure data logger is in place and recording.
						IF ALARM WENT OF
						Clear MIN/MAX and alar Post*Do Not Use Vaccin Alert your supervisor an clinic protocol. Ensure data logger is stil
						and recording. 5. Contact the vaccine Manufacturer to determi vaccine viability before us

Off Site Storage Resources

Other Important Reminders...

Check standing orders to ensure they are clinically accurate and signed by a physician within the past 12 months Have emergency protocols available and ready to be implemented (check expiration date for Epinephrine) Same clinic standards apply when outside the clinic walls (providing VIS, administration documentation, screening for eligibility status and contraindications, additional agency requirements (e.g. written consent?), disposal of syringes, etc.).

Suggested items...

Immunization Action Coalitionhttp://www.immunize.org/catg.d/p3046.pdf

Supplies You May Need at an Immunization Clinic

Summary of Recommendations for

Immunization record cards for patients

Adult Immunization[‡]

(pediatric and adult)[§]

Release of information forms

Vaccines you may need* Select the ones you need for the age of the patient you expect at your clinic.

Refrigerated (MMR may also be frozen)

Diphtheria, tetanus, and pertussis (DTaP) DTaP-HepB-IPV (Pediarix) DTaP-IPV/Hib (Pentacel) DTaP-IPV (Kinrix, Quadracel) Haemophilus influenzae type b (Hib) Hib-MenCY (MenHibrix) Hepatitis A (HepA) Hepatitis B (HepB) HepA-HepB (Twinrix) HepB-Hib (Comvax) Human papillomavirus (HPV) □ Influenza, injectable (IIV) (in season) Influenza, live attenuated intranasal (LAIV) (in season) Measles, mumps, rubella (MMR) Meningococcal ACWY Meningococcal B Pneumococcal conjugate (PCV13) Pneumococcal polysaccharide (PPSV23) Polio, inactivated (IPV) Rotavirus (RV) □ Tetanus-diphtheria, adult (Td) □ Tetanus, diphtheria, and pertussis (Tdap) □ Diluent[†] for ActHIB, Hiberix, MMR, Men-Hibrix, Menveo, Pentacel, and Rotarix Frozen (Never pack frozen vaccine with dry ice) Measles, mumps, rubella, varicella (MMRV) Varicella Zoster Diluent[†] for MMRV, Varivax, and Zostavax For instructions on how to pack and transport vaccines, go to www.cdc.gov/vaccines/recs/storage/toolkit/ storage-handling-toolkit.pdf, pages 69-72. Immunization Clinic Documentation □ Vaccine standing orders and protocols[‡] Vaccination administration record sheets[‡] (i.e., medical records, if needed) □ Billing forms, if needed

Vaccine Adverse Events Reporting (VAERS) forms Schedules, including dates and times. of future immunization clinics Emergency Supplies* Medical Management of Vaccine Reactions in Children and Teens® Medical Management of Vaccine Reactions in Adults[‡] First-line medication Epinephrine, aqueous 1:1000 dilution, in ampules, vials of solution, or prefilled syringes, including epinephrine autoinjectors (e.g., EpiPen and Auvi-O). If autoinjectors are stocked, at least 3 should be available (both pediatric and adult formulation, as needed). Second-line medications: H, antihistamines (either or both of these) Diphenhydramine (e.g., Benadryl) oral (12.5 mg/5 mL liquid, 25 or 50 mg capsules/tablets) or injectable (50 mg/mL solution) Hydroxyzine (e.g., Atarax, Vistaril) oral (10 mg/5 mL or 25 mg/5 mL liquid, 10 mg or 25 mg tablets, or 25 mg capsules) Other supplies for emergencies: □ Syringes (1 and 3 cc) and needles (22 and 25g, 1", 11/2", and 2") for epinephrine or diphenhydramine □ Alcohol wipes Tourniquet □ Pediatric and adult airways (small, medium, and large) Pediatric and adult size pocket masks with one-way valve

- Screening Checklist for Contraindications to Vaccines for Children and Teens® Screening Checklist for Contraindications
- Sphygmomanometer (child, adult, and to HPV, MCV4, and Tdap for Teens^{\$} extra-large cuffs) Tongue depressors

Oxygen (if available)

Stethoscope

- Screening Checklist for Contraindications □ Light source (e.g., flashlight for examinato Vaccines for Adults? tion of mouth and throat) Summary of Recommendations for Wristwatch with a second hand or other
- Child/Teen Immunization[‡] timing device
 - Telephone access to call 911

Vaccine and Miscellaneous Supplies*

- Appropriate storage units and monitoring equipment (thermometers) to maintain vaccine cold chain (see www.eziz.org/ assets/docs/IMM-983.pdf)
- □ 1 or 2 needle disposal "sharps" containers □ 1 box of 3 cc syringes
- 22 and 25g needles
- □ 5/s"; □ 11; □ 11/2"; □ 2"
- □ 1 box of medical gloves (appropriate size range for staff)
- Alcohol wipes
- Spot bandaids Rectangular bandaids
- 1" gauze pads or cotton balls
- □ Thermometers along with probe covers
- Certified calibrated thermometer for vaccine cooler, if needed
- Paper towels
- Bleach solution in spray bottle

Vaccine Information Statements (VISs)*

Most current version associated with each vaccine used in the clinic (available in English and over 30 languages at www.immunize.org/vis)

Office Supplies

- Stapler/staples Calendar Tape Pens □ Paper clips File folders D Post-its C Scissors Pad of paper
- * Always check the expiration dates of all vaccines, medications, and medical supplies before using! In addition, be sure to check that you have the most current versions of the VISs. To learn more about VISs, visit www.immunize.org/vis, † Diluent should never be frozen. + These materials are available at www.immunize. org/handouts § These materials may be purchased at www.immunize. org/shop

Technical content reviewed by the Centers for Disease Control and Prevention


IMMUNIZATION ACTION COALITION Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org


www.immunize.org/catg.d/p3046.pdf • Item #P3046 (9/15)



ADDITIONAL HEPATITIS A VACCINATION RESOURCES

- CDC You Call the Shots Storage and Handling Training https://www2a.cdc.gov/nip/isd/ycts/mod1/courses/sh/ce. asp
- Adult Hepatitis A Vaccine Package Inserts
 - https://www.fda.gov/downloads/biologicsbloodvacci nes/vaccines/approvedproducts/ucm224555.pdf
 - <u>https://www.fda.gov/downloads/biologicsbloodvacci</u> <u>nes/vaccines/approvedproducts/ucm110049.pdf</u>
- 2018 Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States <u>https://www.cdc.gov/vaccines/schedules/downloads/adul</u> <u>t/adult-combined-schedule.pdf</u>
- Vaccine Manufacturer/Distributor Contact List (pg. 63) CDC Vaccine Storage & Handling Toolkit <u>https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit</u> /index.html
- Hepatitis A Vaccine Information Statement
 <u>https://www.cdc.gov/vaccines/hcp/vis/vis-</u>
 <u>statements/hep-a.pdf</u>







Questions?

Justin Albertson MS Zack Moore MD, MPH Gibbie Harris MSPH, BSN, RN Beth Meadows MSN, RN Susan Sullivan MS, RN-BC